Barbie with type 1 diabetes, glucose monitor launched by Mattel. Check features, images
has been introduced in first-ever Type 1
Diabetes
avatar with a
glucose monitor
by Mattel. Barbie -- with her tiny waist, long legs and eternally slender physique -- has long looked the same. Now she proudly displays her insulin pump, while wearing a polka-dotted outfit that matches her blue high-heeled boots and blue purse. She also has a pink continuous glucose monitor on her arm. The medical equipment is accurate and the fabric print -- blue circles -- is a global symbol of diabetes awareness. The company released the Barbie with Breakthrough T1D, an advocacy and research organization with the goal of finding a cure for diabetes.
Why is this Diabetes Barbie?
Over at least the last couple of decades, Mattel has responded to criticism of its unrealistic beauty standards by creating dolls that reflect a wider segment of society. The company continued that push with its newest doll: Barbie with Type 1 diabetes.
Tens of millions of Americans have some form of diabetes. Type 1 diabetes is a chronic autoimmune disease that causes the pancreas to make very little insulin or none at all. Unlike Type 2 diabetes, which usually emerges slowly in adulthood and can sometimes be reversed early on with exercise and dietary changes, Type 1 often strikes in childhood or adolescence.
Agencies
Source: Shop.mattle.com
Live Events
Managing diabetes can be difficult. People with the disease have to monitor sugar levels and inject insulin around the clock. It can also lead to complications including heart disease, blindness, kidney damage and the possibility of losing a limb to amputation.
On TikTok and Instagram, some users with Type 1 diabetes expressed their joy with the new Barbie, some sharing emotional posts about seeing their disease represented.
Evolution of Barbie Doll
Barbie, one of the most successful dolls of all time, was criticized for a period in the early 2000s as other companies started to manufacture more diverse and inclusive dolls while she continued to look roughly the same as her 1959 self. In 2010, the company apologized for a book about
Barbie
and computers that critics said was sexist. Since then, the company has worked to reinvent Barbie.
Agencies
The newest Barbie is part of Mattel's Fashionistas line, which the company has called its "most diverse doll line." Last year, Mattel introduced a blind Barbie, who has a red-and-white cane with a marshmallow roller tip and sunglasses suited for light-sensitive eyes.
In 2019, Mattel released a Barbie in a wheelchair and a Barbie with a prosthetic limb. Other dolls in the Fashionistas line include a Barbie with Down syndrome, a Barbie with hearing aids, a bald Barbie, a Barbie with a skin condition and Barbies with different hair types and body shapes.
FAQs
Q1. What is the name of Hollywood movie based on Barbie?
A1. And in 2023, Barbie's favorite color -- bright pink, obviously -- catapulted back to the center of popular culture with the release of "Barbie," the movie directed by Greta Gerwig that earned $1.4 billion worldwide.
Q2. Who manufactures Barbie doll?
A2. Mattel manufactures the Barbie doll.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
12 hours ago
- Economic Times
Are we chasing longevity all wrong? Top doctor's candid post urges shift from biohacking, anti-aging obsession
iStock Dr. Sanjay Bhojraj, a US-based heart specialist, warns against the rising trend of biohacks and anti-aging fads, stating that Americans spend over 12 years in poor health before death (Image: iStock) In a world obsessed with living longer, are we overlooking what really matters—living well? In a powerful and emotionally charged Instagram post, Dr. Sanjay Bhojraj, a leading US-based interventional cardiologist and founder of the Well12 wellness program, challenged the very foundation of the modern longevity movement. His message? A longer life doesn't mean a better one. 'Longevity is everywhere… but we're not living better,' reads the text of his viral post. Surrounded by trends like cold plunges, anti-aging supplements, and flashy biohacks, many today are chasing added years with little thought to what those years actually look like. Dr. Bhojraj argues that while medical advancements may have stretched the average lifespan, they've done little to prevent a painful truth: Americans now spend over 12 years in poor health toward the end of their lives. 'That's more than a decade of daily meds, low energy, pain, and cognitive decline,' he wrote in his caption, adding that we've succeeded in extending life—but at the cost of vitality and dignity. The sobering reality, he notes, is that we're 'just living longer… while sicker.' His post strikes at the heart of the longevity narrative, exposing a hard truth often hidden beneath headlines and health fads. Dr. Bhojraj's solution isn't found in another supplement or a viral health hack—it's in reframing the conversation. 'Living longer doesn't necessarily mean living better,' he stated. 'It's time to shift the conversation from merely adding years to ensuring those years are vibrant and fulfilling.' This, he explains, is the distinction between lifespan and healthspan—a term increasingly used by health professionals to emphasize not just how long one lives, but how well. The cardiologist, known for combining evidence-based medicine with holistic wellness, has long advocated for addressing the root causes of disease. His integrative approach blends nutrition, genomics, breathwork, sleep, and stress management—an ecosystem of habits meant to extend vitality, not just life. He urges patients and practitioners to focus less on living forever and more on feeling alive. 'Let's redefine what it means to age well,' his post concludes—a sentiment that resonates deeply in a time where longevity often overshadows quality. Dr. Bhojraj's post is more than a medical observation; it's a cultural critique. It reminds us that the true goal of health isn't merely to survive more birthdays—but to live each year with energy, clarity, and purpose. In the race for longer lives, he challenges us to pause and ask: what are we really running toward?
Time of India
13 hours ago
- Time of India
Are we chasing longevity all wrong? Top doctor's candid post urges shift from biohacking, anti-aging obsession
A decade of decline is not a win Why healthspan matters more than ever In a world obsessed with living longer, are we overlooking what really matters—living well? In a powerful and emotionally charged Instagram post, Dr. Sanjay Bhojraj, a leading US-based interventional cardiologist and founder of the Well12 wellness program, challenged the very foundation of the modern longevity movement. His message? A longer life doesn't mean a better one.'Longevity is everywhere… but we're not living better,' reads the text of his viral post. Surrounded by trends like cold plunges, anti-aging supplements, and flashy biohacks , many today are chasing added years with little thought to what those years actually look like. Dr. Bhojraj argues that while medical advancements may have stretched the average lifespan, they've done little to prevent a painful truth: Americans now spend over 12 years in poor health toward the end of their lives.'That's more than a decade of daily meds, low energy, pain, and cognitive decline,' he wrote in his caption, adding that we've succeeded in extending life—but at the cost of vitality and dignity. The sobering reality, he notes, is that we're 'just living longer… while sicker.' His post strikes at the heart of the longevity narrative, exposing a hard truth often hidden beneath headlines and health Bhojraj's solution isn't found in another supplement or a viral health hack—it's in reframing the conversation. 'Living longer doesn't necessarily mean living better,' he stated. 'It's time to shift the conversation from merely adding years to ensuring those years are vibrant and fulfilling.' This, he explains, is the distinction between lifespan and healthspan—a term increasingly used by health professionals to emphasize not just how long one lives, but how cardiologist, known for combining evidence-based medicine with holistic wellness, has long advocated for addressing the root causes of disease . His integrative approach blends nutrition, genomics, breathwork, sleep, and stress management—an ecosystem of habits meant to extend vitality, not just urges patients and practitioners to focus less on living forever and more on feeling alive. 'Let's redefine what it means to age well,' his post concludes—a sentiment that resonates deeply in a time where longevity often overshadows Bhojraj's post is more than a medical observation; it's a cultural critique. It reminds us that the true goal of health isn't merely to survive more birthdays—but to live each year with energy, clarity, and purpose. In the race for longer lives, he challenges us to pause and ask: what are we really running toward?
Mint
14 hours ago
- Mint
FDA Offers to Trade Faster Drug Reviews for Lower US Prices
Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that 'equalize' the cost of their medicines between the US and other countries, an unusual proposition from the regulator that's long avoided contentious pricing debates. The comments, made in an interview on Bloomberg Television's Wall Street Week with David Westin, offer insight into an idea floated to help the administration achieve one of President Donald Trump's main health-care goals: ensuring foreign countries aren't getting a better deal on drugs. Trump demanded that Americans get similar or lower prices as consumers in other countries in an executive order signed in May. Price adjustments may give companies another way to obtain 'national priority vouchers,' the reward that comes as part of a new program the FDA announced last month that would slash review times for companies it says are backing national interests. Makary didn't offer details about how drugmakers would have to adjust their prices to qualify for a voucher. 'We can issue a national priority review voucher for companies that are promising to equalize the price' between the US and what other foreign countries pay, Makary said. 'We want to incentivize good behavior in the marketplace, and these priority vouchers are worth a lot of money.' The new vouchers would cut review times to one to two months, down from an average of about 10 months to one year now, the agency said. In the interview, Makary said the program could be used as a tool to even out drug prices with those currently charged in places like Europe. The Department of Health and Human Services has asked drugmakers to price therapies that don't have generic competition at the lowest level offered to any member country in the Organization for Economic Cooperation and Development that has an economy at least 60% of the size of the US on a per capita basis. The FDA typically has avoided inserting itself into the murky world of drug pricing in the US. Explicitly trading faster reviews for price changes on existing treatments would be abnormal for the agency, which doesn't have authority 'to investigate or control the prices charged for marketed drugs.' It's also unclear how much of an impact the vouchers would have. Makary touted the value of pediatric priority review vouchers offered under a different program, which is currently coming to an end. He noted that some have sold for more than $100 million in a secondary market, which was legal. The new national priority vouchers can't be sold. Drugmakers also have limited control over what patients ultimately pay in the US, where a complex system of insurance companies and drug benefit managers typically operates in the space between where a patient is given a prescription and where they get their medicine from a pharmacy. Still, the approach could offer a financial incentive for drugmakers to lower drug prices. When Trump pursued equalizing costs in the US with those abroad during his first term, he exclusively used a more punitive approach, issuing regulations that would have reduced what Medicare, the health insurance program for the elderly and disabled, pays for medications administered in physicians' offices. In the initial announcement of the voucher program, FDA said they could be offered to return drug manufacturing to the US, address health crises or unmet public health needs, or provide innovative cures. The interview will air Friday at 6 p.m. in New York.
